Skip to main
IONS
IONS

Ionis Pharma (IONS) Stock Forecast & Price Target

Ionis Pharma (IONS) Analyst Ratings

Based on 26 analyst ratings
Buy
Strong Buy 31%
Buy 27%
Hold 35%
Sell 4%
Strong Sell 4%

Bulls say

Ionis Pharmaceuticals is experiencing a positive outlook driven by robust performance in R&D revenue, which amounted to $141 million, surpassing expectations and underpinned by favorable payer dynamics with a high percentage of patients incurring $0 out-of-pocket costs. The company has successfully expanded its portfolio with solid contributions from products such as Wainua, which generated $42 million in sales in the fourth quarter of 2024, resulting in $10 million in royalty revenue for Ionis. Additionally, the firm's optimism regarding its pipeline, including promising Phase III trial results and a strong shift in patient preferences towards its latest offerings, positions Ionis favorably in the growing therapeutic market for rare and chronic diseases.

Bears say

Ionis Pharmaceuticals is projected to continue incurring substantial losses, with no anticipated profitability for several years. The company has revised its revenue guidance for 2025, forecasting a bottom-end revenue of $600 million, which is below the $670 million consensus estimate and reflects a year-over-year decline driven by lower R&D revenue. Additionally, Ionis faces significant risks, including potential market share erosion of Spinraza due to competitive pressures, a failure to translate impressive reductions in lipoprotein(a) to cardiovascular outcomes, and delays in unlocking the full value of their platform beyond liver-targeted therapies.

Ionis Pharma (IONS) has been analyzed by 26 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 27% recommend Buy, 35% suggest Holding, 4% advise Selling, and 4% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ionis Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ionis Pharma (IONS) Forecast

Analysts have given Ionis Pharma (IONS) a Buy based on their latest research and market trends.

According to 26 analysts, Ionis Pharma (IONS) has a Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ionis Pharma (IONS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.